Differential expression of E2F transcription factor 1 in triple negative breast cancer.

Triple Negative ◽

Primary Tumors ◽

Free Survival ◽

Ductal Cells ◽

E2f Transcription Factor ◽

Transcription Factor 1

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding E2F transcription factor 1, E2F1, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). E2F1 was also differentially expressed in bulk tumor in human breast cancer (3). E2F1 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of E2F1 in primary tumors of the breast was correlated with distant metastasis-free survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of E2F1 was correlated with recurrence-free survival in patients with mesenchymal stem-like subtype disease. E2F1 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of maternal embryonic leucine zipper kinase in triple negative breast cancer.

10.31219/osf.io/g6brv ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Leucine Zipper ◽

Triple Negative ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding maternal embryonic leucine zipper kinase, MELK, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). MELK was also differentially expressed in bulk tumor in human breast cancer (3). MELK mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of MELK in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of MELK was correlated with distant metastasis-free survival in patients with basal-like 1 and luminal androgen receptor subtype disease. MELK may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of mitochondrial ribosomal protein L13 in triple negative breast cancer.

10.31219/osf.io/rvb95 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Ribosomal Protein ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Recurrence Free Survival ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding mitochondrial ribosomal protein L13, MRPL13, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). MRPL13 was also differentially expressed in bulk tumor in human breast cancer (3). MRPL13 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of MRPL13 in primary tumors of the breast was correlated with recurrence-free survival in patients with basal-like, luminal A, luminal B and HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of MRPL13 was correlated with recurrence-free survival in patients with basal-like 1 subtype disease. MRPL13 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of RecQ-like helicase 4 in triple negative breast cancer.

10.31219/osf.io/kphyr ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Significant Differential Expression ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding RecQ-like helicase 4, RECQL4, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). RECQL4 was also differentially expressed in bulk tumor in human breast cancer (3). RECQL4 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of RECQL4 in primary tumors of the breast was correlated with recurrence-free survival in patients with HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of RECQL4 was correlated with distant metastasis-free survival in patients with basal-like 2 subtype disease. RECQL4 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 3, H2a in triple negative breast cancer.

10.31219/osf.io/89ceb ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Significant Differential Expression ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer are predicted to benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 3, H2a, HIST3H2A, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST3H2A was also differentially expressed in bulk tumor in human breast cancer (3). HIST3H2A mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST3H2A in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A and HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of HIST3H2A was correlated with distant metastasis-free survival in patients with immunomodulatory, mesenchymal, and luminal androgen receptor subtype disease. HIST3H2A may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of transcription factor Dp family member 3 in triple negative breast cancer.

10.31219/osf.io/9gyt5 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Transcription Factor ◽

Family Member ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer are predicted to benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding transcription factor Dp family member 3, TFDP3, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). TFDP3 was also differentially expressed in the brain metastases of patients with brain metastatic breast cancer (3). TFDP3 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of TFDP3 in primary tumors of the breast was correlated with distant metastasis-free survival in patients with basal-like and luminal B type cancer, while within triple negative breast cancer, primary tumor expression of TFDP3 was correlated with overall survival in patients with basal-like 1 subtype disease. TFDP3 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 1, H2bd in triple negative breast cancer.

10.31219/osf.io/5fcwd ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Significant Differential Expression ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bd, HIST1H2BD, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BD was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2BD mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BD in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A, HER2+ and normal-like subtype cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BD was correlated with distant metastasis-free survival in patients with basal-like 1 subtype disease. HIST1H2BD may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of ribonucleotide reductase regulatory subunit M2 in triple negative breast cancer.

10.31219/osf.io/5vhyc ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Ribonucleotide Reductase ◽

Triple Negative ◽

Regulatory Subunit ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding ribonucleotide reductase regulatory subunit M2, RRM2, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). RRM2 was also differentially expressed in bulk tumor in human breast cancer (3). RRM2 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of RRM2 in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of RRM2 was correlated with distant metastasis-free survival in patients with luminal androgen receptor subtype disease. RRM2 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 1, H2am in triple negative breast cancer.

10.31219/osf.io/ctqj4 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Recurrence Free Survival ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2am, HIST1H2AM, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2AM was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2AM mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2AM in primary tumors of the breast was correlated with recurrence-free survival in patients with normal-like type cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2AM was correlated with recurrence-free survival in patients with basal-like 1 subtype disease. HIST1H2AM may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of kinesin family member 20A in triple negative breast cancer.

10.31219/osf.io/4f7kp ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Distant Metastasis ◽

Triple Negative ◽

Primary Tumors ◽

Free Survival ◽

Ductal Cells ◽

Distant Metastasis Free Survival ◽

Kinesin Family

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding kinesin family member 20A, KIF20A, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). KIF20A was also differentially expressed in bulk tumor in human breast cancer (3). KIF20A mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of KIF20A in primary tumors of the breast was correlated with distant metastasis-free survival in patients with luminal B type cancer in patients with HER2+ cancer, and in patients with normal-like cancer, while within triple negative breast cancer, primary tumor expression of KIF20A was correlated with distant metastasis-free survival in patients with basal-like 2 subtype disease. KIF20A may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of kinesin family member 23 in triple negative breast cancer.

10.31219/osf.io/meszx ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Family Member ◽

Tumor Cells ◽

Triple Negative ◽

Recurrence Free Survival ◽

Primary Tumors ◽

Free Survival ◽

Ductal Cells ◽

Kinesin Family

Women diagnosed with triple negative breast cancer are predicted to benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding kinesin family member 23, KIF23, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). KIF23 was also differentially expressed in bulk tumor in human breast cancer (3). KIF23 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of KIF23 in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A and luminal B type cancer, while within triple negative breast cancer, primary tumor expression of KIF23 was correlated with recurrence-free survival in patients with basal-like 1 subtype disease. KIF23 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.